The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
£1.58 now -- who would have thought it. Frankly there seems no limit to the drop in this share. What a disaster. I scoffed when Shaun P sold out in a huff at £4 plus after the DHSC debacle -- he must be laughing his head off now. NCYT is like the poverbial albatross around one's neck and I am suffering big time like so many on this forum. I would jump at £4 now and move on to pastures new.
This may sound an odd question but would treatment for Asthma warrant a lower or higher degree of efficacy from P3 result than Covid my thinking being that should the degree of P3 result be less than hoped for Covid (I am sure it won't be), it would nevertheless still be extremely advantageous regards Asthma. You can perhaps see where I am coming from as Asthma must be a massive market which has been around for donkeys years and unlikely to disappear.
There is understandably much bitterness following yesterday's RNS but why do some regular posters consistently engage with the increasing numbers of Trolls determined to diminish the SP? You must surely either have far too much time on your hands or insist on having the last word. You are doing this forum no favours by pandering to these sad people so why not bin them and give the rest of us a break from the continual sniping and concentrate on the future prospects of this concern? DA looked ill yesterday and although he gave reasonably decent replies to questions, he hardly left me punching the air with excitement. QUESTION: How many non Covid products if any are awaiting CDTA approval? I suspect now that DA has shown his face to PIs, we will see more of him before April given his marketing background. He will want, hopefully, to give a more upbeat performance and cannot be too happy with yesterday's effort. We appear to have an extremely strong team and what with a DHSC settlement of sorts possible soon , I can see Nova drag itself slowly out of the mire, heading towards a bright future.
...for SNG to publish P3 results whilst power mad Putin is poised on invading Ukraine. Even if results were spectacular I doubt the SP would soar much if anything and publicity could be muted. Better to wait a few weeks more until the dust settles -- hopefully!
Should not be surprised the SP is approaching £2.50 even with results due despite likely healthy sales. What concerns me is the seeming almost total lack of news on any of the various exciting areas we are told exist. Most companies of repute would have managed to give some sort of feedback by now but not Nova so one has to speculate what game BODS are playing or is the simple truth that there has been no real progress hence the continued collapse in SP. No wonder IIs are keeping a wide berth and I must confess I am becoming rather distrustful of our new CEO -- what is he hiding?
You have got to admire DA and his band of merrie men. His timing is perfect what with the latest relaxation of Covid rules ensuring the SP will continue to drop steadily up to result date and nearer £2 than £3. He is no fool and this could lead to a management buyout or TO finally getting rid of all those moaning pesky PIs. I take my hat off to him!
Tkr. Why should they worry... few directors have any skin in the game. Its only PIs who are losing hand over foot. They could have stopped the rot quite easily to some extent but have absolutely no interest in us. I expect the SP to continue to drop over next week or so and like a few others have no great expectation of a massive rise unless there is a TO. For me now with the calibre of this Bod it's get out as quickly as possible... a damage limitation job.
I am very aware of that but even at Nova's lowly level surely a couple of phrases cribbed from this RNS may have worked wonders over the past 6 months. Let me ask you question -- if you were CEO of this company would you ignore your shareholders completely given the dire situation of the SP - maybe not affecting pensions but nevertheless certainly hitting the pocket of many in a serious way. There is no excuse and DA has a lot to prove!
...compared to the mighty Unilever but note how quickly they responded to a 7% SP drop today virtue an RNS. They are not a company to issue a RNS lightly. Our PR dept or even illustrious leader could easily have put something out along these lines but no, they/he maitain a stubborn deafening silence and have lost credability in my book.Have they no good news to I suspect some skulduggery is afoot but we are powerless. Like many others, I cannot wait to leave Nova once I claw back some losses. Hopefully there will be some light at end of month but I am not so sure now. A fe Mon, 17th Jan 2022 07:01
RNS Number : 6408Y
Unilever PLC
17 January 2022
Unilever update
London, 17 January 2022. The management and Board of Unilever are committed to accelerating the company's growth and repositioning the portfolio into higher growth categories. As a result of the reporting of Unilever's interest in GSK Consumer Healthcare, we are today bringing forward a planned update, setting out the strategic direction that the company is pursuing.
Unilever's strategic direction
Following the unification of Unilever, the Board has undertaken an extensive process to review strategic pathways to reposition Unilever's portfolio into higher growth categories.
This concluded that Unilever's future strategic direction lies in materially expanding its presence in Health, Beauty, and Hygiene. These categories offer higher rates of sustainable market growth, with significant opportunities to drive growth through investment and innovation, and by leveraging Unilever's strong presence in emerging markets.
The Board also concluded that major acquisitions should be accompanied by the accelerated divestment of intrinsically lower growth brands and businesses. This would provide funding and enable separation dis-synergies to be offset by acquisition synergies.
Unilever is committed to strict financial discipline to ensure that acquisitions create value for shareholders. The company benefits from a strong balance sheet and cash generation, and remains committed to maintaining an A-band credit rating. Following any acquisition, the company would target a return to current levels of gearing over the short to medium term.
Consumer Health is an attractive strategic option
Consumer Health is a highly complementary category for Unilever, with good potential for synergies and a number of routes to build scale.
GSK Consumer Healthcare would be a strong strategic fit. 45% of GSK Consumer Healthcare is in Oral Care and VMS - categories in which Unilever already has presence and substantial capabilities. OTC would be an attractive adjacent category, with the ability to combine Unilever's consumer and branding expertise with GSK Consumer Health's technical OTC capabilities. The acquisition would create scale and a growth platform for the combined portfolio in the US, China, and India, with further opportunities in other emerging markets.
We believe that this
I think many of us here share Poidster's anger. It is perplexing why there has not been one single attempt for ages to put SHs minds at rest re the demise of the SP. It is not rocket science and many companies would have issued a short statement by now without it infringing anything of a confidential nature. Long silences like these in my bitter experiece does not bode well so I am not expecting a euphoric statement end of month. Not sure rattling their cage will make one iota of difference before then. Will give it until April to decide what to do but currently thinking of selling a chunk of my considerable holding to increase stake in SNG who await imminent result of P3 trial. What a difference in the approach from their CEO who goes out of his way to keep SHs informed! DA is a big disappointment and one wonders what game he is playing..
This about sums it up! Jacob Rees-Mogg has claimed Scottish Tory leader Douglas Ross is a “lightweight figure” in the political party. The Conservative MP, who also serves as leader of the House of Commons, made the comments after Ross said the Prime Minister’s position was “untenable” after he admitted attending a lockdown party at Downing Street. Will do wonders for our relations with Scotland! You could not make it up!
PathFlow® COVID-19 Rapid Antigen is a self-test LFT to detect SARS-CoV-2
antigens using oral fluid samples and provides results in approximately 15 minutes.
This test demonstrated a sensitivity of 90.1% and specificity of 99.3% from 303
clinical samples. The test offers mass screening for home, travel, events, and
workplace markets. Novacyt expects to make this LFT available as a CE Marked
product shortly. (Ahem!)